Financings Routine +

APOTEX HEALTH CORP. ANNOUNCES CLOSING OF UPSIZED INITIAL PUBLIC OFFERING AND EXERCISE OF OVER-ALLOTMENT OPTION IN FULL

Canadian pharma giant debuts on TSX with $1.5B capital raise, trading at a premium to IPO price

By The Northwire Desk — AI Analysis Jun 16, 2026 · 08:58 APTX · 28.6 APOTEX HEALTH CORP

Executive Summary

Apotex Health Corp. closed its upsized initial public offering (IPO) on the Toronto Stock Exchange (TSX) under the ticker APTX.
The offering consisted of 62,291,670 common shares priced at $24.00 per share, generating total gross proceeds of approximately $1.495 billion.
Proceeds are split between a primary treasury offering of ~35.4 million shares yielding ~$850 million to Apotex, and a secondary offering of ~26.9 million shares by SK Capital Partners and other existing shareholders yielding ~$645 million.
The underwriters' over-allotment option was exercised in full, adding 8,125,000 shares to the secondary offering, with proceeds going entirely to selling shareholders.
SK Capital Partners reduced its ownership stake from ~75.3% to ~52.4% post-offering, while Sherfam (API Investment LP) was diluted from ~16.8% to ~14.2%.
The transaction was co-led by major Canadian banks (RBC, TD, Scotiabank) and completed pursuant to a supplemented PREP prospectus dated June 10, 2026.

Material Impact

The closing confirms the successful completion of a major capital raise, but the event was fully anticipated and priced weeks in advance.
The stock has already traded at a significant premium to the IPO price, opening at $27.00 on June 10 and reaching $28.99 by June 12, indicating the market has already priced in the offering.
The full exercise of the over-allotment option signals strong institutional demand, which typically provides a liquidity floor and supports the initial valuation.
However, the secondary offering represents substantial insider selling (~$645 million), with SK Capital offloading a meaningful portion of its stake. This reduces insider alignment and introduces near-term selling pressure that could cap upside.
The $850 million in primary proceeds will strengthen the balance sheet, but without disclosed use-of-proceeds or financials, the immediate operational impact is neutral.

APTX · Price

Company Overview

Apotex Health Corp. is the largest Canadian-based pharmaceutical company, headquartered in Toronto with regional offices in the United States, Mexico, and India.
The company operates a broad portfolio spanning generic, biosimilar, and innovative branded pharmaceuticals, alongside consumer health products.
Strategic positioning emphasizes delivering affordable, high-quality medicines and serving as a preferred health partner in the Americas for pharmaceutical licensing and product acquisitions.
The company completed one of the largest life sciences IPOs in TSX history by total proceeds.

More from APOTEX HEALTH CORP